Neurocrine biosciences launches ingrezza® sprinkle (valbenazine) capsules to ease administration for patients experiencing dysphagia or difficulty swallowing

San diego , july 18, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the launch of a new sprinkle formulation of ingrezza® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (vmat2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with huntington's disease.1 ingrezza® sprinkle (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute ingrezza. "only ingrezza offers a sprinkle formulation to ease administration for individuals living with tardive dyskinesia or huntington's disease chorea, who often have difficulty swallowing pills," said eiry w.
NBIX Ratings Summary
NBIX Quant Ranking